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Abstract
The present review synthetically describes the currently advanced hypotheses for a neurobiological
basis of depression, ranging from the classical monoaminergic to the more recent neurotrophic
hypothesis. Moreover, the Authors review the available preclinical and clinical evidence suggesting
a possible role for the endocannabinoid system in the physiopathology of depression. Indeed, in
spite of the reporting of conflicting results, the pharmacological enhancement of endocannabinoid
activity at the CB1 cannabinoid receptor level appears to exert an antidepressant-like effect in
some animal models of depression. On the contrary, a reduced activity of the endogenous
cannabinoid system seems to be associated with the animal model of depression, namely the
chronic mild stress model. Moreover, a few studies have reported an interaction of antidepressants
with the endocannabinoid system. With regard to clinical studies, several authors have reported an
alteration of endocannabinoid serum levels in depression, while post mortem studies have
demonstrated increased levels of endocannabinoids associated to a concomitant hyperactivity of
CB1 receptor in the prefrontal cortex of suicide victims. No clinical trials carried out using
cannabinoids in the treatment of affective disorders have been published to date, although
anecdotal reports have described both antidepressant and antimanic properties of cannabis as well
as the ability of cannabis to induce mania that has also been documented. These findings are
discussed, leading us to conclude that, although data available are sufficient to suggest a possible
involvement of the endogenous cannabinoid system in the neurobiology of depression, additional
studies should be performed in order to better elucidate the role of this system in the
physiopathology of depression.
Introduction
The present paper provides a synthetic review of the cur-
rent neurobiological hypotheses of depression, taking
into account preclinical and clinical evidence suggesting a
possible involvement of the endogenous cannabinoid
system in the physiopathology of depression.
Indeed, pharmacological manipulations of the endocan-
nabinoid system have elicited antidepressant-like effects
in animal models of depression. Moreover, some animal
models of depression seem to be associated to alterations
in the endocannabinod system.
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Although no clinical trials performed using cannabinoids
in the treatment of affective disorders have been pub-
lished to date, anecdotal reports have described both anti-
depressant and antimanic properties of cannabis.
However, cannabis abuse has been associated with the
induction of psychosis and with the worsening of the
course of manic-depressive disorders.
Finally, several studies have reported an interaction
between antidepressants and the endocannabinoid sys-
tem. Other studies have suggested that depression might
be associated with alterations of endocannabinoid serum
levels.
Current hypotheses on the neurobiology of 
depression
The neurobiological hypotheses of depression are essen-
tially based on the mechanism of action of antidepressant
drugs.
The first hypothesis was proposed more than 40 years ago,
following the serendipitous discovery of the antidepres-
sant effect of monoaminoxidase inhibitor (MAOI) and
imipramine. This hypothesis (the monoamine hypothesis
of depression) postulates that depression is associated
with a reduced monoaminergic transmission, in particu-
lar noradrenaline (NA) and serotonin (5HT) in the CNS
[1].
The monoamine hypothesis of depression has led to the
development of the more recent antidepressant drugs,
namely the selective serotonin reuptake inhibitors (SSRI)
and the selective noradrenaline reuptake inhibitors
(SNRI). According to the monoamine theory of depres-
sion, these drugs are capable of increasing serotonin or
noradrenaline levels in the synaptic cleft by inhibiting
their presynaptic reuptake [2].
Although the numerous investigations aimed at demon-
strating a monoaminergic deficiency in depressed patients
have reported conflicting and inconclusive results[3], in
our opinion the updated monoamine hypothesis [4-7]
still constitutes a fundamental basis for the development
of new antidepressants.
However, the above theory is not able to provide any
explanation for the clinical observation that the therapeu-
tic action of these drugs is manifested only following sev-
eral weeks of treatment, while an increased
monoaminergic transmission is induced immediately.
This discrepancy has generated the concept that the
increase in monoaminergic transmission is manifested
initially, but is not sufficient to exert an antidepressant
effect. The therapeutic action of these drugs is likely asso-
ciated to the neurobiological effects induced following
chronic administration [8].
This consideration has led researchers to investigate the
effects induced by long-term treatment with antidepres-
sants.
Long-term administration of antidepressants is capable of
modifying both the number and sensitivity of different
monoaminergic receptors [8]. A detailed description of
these results is beyond the scope of the present review.
It has moreover been demonstrated, by both our group
and other authors [9] that chronic treatment with various
antidepressants, including electroconvulsive therapy
(ECT) and SSRI, produces an increase in the activity of the
mesolimbic dopaminergic system, which plays an essen-
tial role in the rewarding mechanism shown to be
impaired in depression [10]. These observations suggest
that depression, and in particular several symptoms of
depression such as anhedonia and lack of motivation,
may be caused by a deficiency in mesolimbic dopaminer-
gic transmission [10], the reinstatement of which is elic-
ited by chronic antidepressant treatment.
However, it has been postulated that psychotic depression
might be associated with an increased dopaminergic
transmission, since patients may be treated successfully
with the combination of antidepressants and antipsychot-
ics [11].
More recently, clinical evidence has been reported indicat-
ing that hippocampal volume is reduced in depression
[12,13].
Neuroimaging studies have reported that reduction in
hippocampal volume is correlated with multiple episodes
of depression in untreated patients [12,13], whereas
patients treated with antidepressants do not display any
loss in hippocampal volume [14,15]. These data suggest
that depression might be associated with hippocampal
cellular loss and/or atrophy that can be counteracted by
adequate antidepressant treatments.
This hypothesis seems to be supported by recent preclini-
cal studies, demonstrating that chronic antidepressants
promote neurogenesis, while animal models of depres-
sion show decreased cell proliferation and neurogenesis.
Indeed, it has been reported that chronic antidepressants,
including ECT, increase cell proliferation and neurogene-
sis [15], the latter being essential in producing an antide-
pressant like effect in animal models of depression [16].Clinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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On the contrary, acute and chronic stress decrease cell pro-
liferation and neurogenesis [17], an effect reversed by
antidepressants[17].
With regard to the mechanism by means of which antide-
pressants produce neurogenesis, the most convincing
hypothesis suggests that antidepressants elicit such an
effect by increasing the levels of neurotrophic factors such
as Brain-Derived Neurotrophic Factor (BDNF)[15,18,19].
Accordingly, long-term antidepressant treatment has been
shown to increase BDNF protein and mRNA levels [19-
21] and reverse the stress-induced decrease in BDNF
[21,22]. Exogenous administration of BDNF displays anti-
depressant-like effects in several animal models of depres-
sion [23]. It may be suggested that [18] long-term
antidepressant treatment up-regulates cAMP pathway
[24], in turn activating the transcription factor cAMP
response element binding protein (CREB)[25], increasing
BDNF gene expression [15,26,27].
Stress plays a key role in precipitating depression; indeed,
it has been postulated that the disorder may be induced
by means of a mechanism possibly related to an increased
corticosterone secretion subsequently leading to a
decrease in neurogenesis.
This same mechanism may also be implicated in depres-
sion associated to hyperactivity of the Hypothalamic-pitu-
itary-adrenal (HPA) axis due to an impaired feed-back
mechanism[28,29]. Indeed, the majority of depressed
patients obtain abnormal results on the dexamethasone
suppression test. This up-regulation produces an increase
of glucocorticoid secretion which may be responsible for
the decrease in cell proliferation [30-32]. Accordingly,
animals lacking glucocorticoid receptors (GR) display an
impaired feed back mechanism and are more susceptible
to the stress-induced depressive behaviour [33].
Moreover, the exogenous administration of glucocorti-
coids produces a decrease in cell proliferation and neuro-
genesis [30-32]. Finally, hippocampal volume loss, a
phenomenon that can be partially reversed once cortisol
levels decrease [34], has been observed in Cushing's syn-
drome.
The endocannabinoid system
A detailed description of the endocannabinoid system is
beyond the scope of this paper. Thus, in this section we
briefly describe those components of the endocannabi-
noid system that act as targets for the pharmacological
interventions aimed at determining the activity of the
endocannabinoid system.
The term "endocannabinoid system" refers to the recently
discovered neuromodulator system comprising cannabi-
noid receptors (which represent the receptors of Tetrahy-
drocannabinol (THC), the major active component of
cannabis) and their endogenous ligands.
To date, two types of cannabinoid receptors have been
identified: CB1 and CB2 receptors [35-38]. These recep-
tors belong to the superfamily of G protein coupled recep-
tors [35,36], the CB1 receptor is widely distributed in the
terminals of neurons[39], while the CB2 receptor is exten-
sively expressed throughout the immune system[40].
However, it has recently been reported that these receptors
are present also in the brain [41,42].
The activation of cannabinod receptors inhibits cAMP
production via its coupling to Gi protein [35,36].
However numerous other signal transduction mecha-
nisms associated with cannabinoid receptors have been
described [43].
The main endogenous ligands (endocannabinoids) of
cannabinoid receptors are anandamide [44] and 2-AG (2-
arachidonoylglycerol) [45,46]. 2-AG is a full agonist at
both CB1 and CB2 receptors but shows less affinity than
anandamide for both receptors [47]. Anandamide is a par-
tial agonist at both CB1 and CB2 receptors, displaying a
higher affinity for the CB1 receptor [38]. Endocannabi-
noids are arachidonic acid derivatives conjugated with
ethanolamine or glicerol. Anandamide is formed by a
phospholipid precursor, the N arachidonylohosphatidyl
ethanolamide (NAPE), and its release from NAPE is cata-
lyzed by a specific phospholipase D (PLD) [48]. The 2-AG
is a monogliceride synthesized by a phosphatidyl inositol
specific phospholipase C(PLC) [40,47].
Following the release of endocannabinoids, these com-
pounds exert an action on cannabinoid receptors and are
rapidly inactivated by uptake and degradation [49]. Endo-
cannabinoid uptake is mediated by a transporter facilitat-
ing the uptake of both anandamide and 2-AG [50].
The degradation of endocannabinoid is achieved by
means of two specific enzymes: the fatty acid amide
hydrolase (FAAH) [51] and the monoacylglyceride lipase
(MAGL) enzymes [52]. FAAH degrades anandamide,
whereas the MAGL degrades 2-AG.
Various compounds interacting at different phases of
endocannabinoid transmission are available to better
study the role of endocannabinoids in numerous patho-
logical and physiological conditions. Accordingly, proc-
esses can be carried out by substances acting as agonists or
antagonists at CB receptors, by drugs inhibiting endocan-
nabinoid transporters and by others inhibiting FAAH
activity. Moreover, very useful tools to study the physio-Clinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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logical and physiopathological role of the endocannabi-
noid system are the CB1 receptor and FAAH Knockout
(KO) mice.
Among the numerous of functions modulated by the
endocannabinoid system [53], the control of emotions
and the regulation of motivational behaviour appear to be
of particular importance for the possible implication of
this system in the pathogenesis of mental disorders such
as drug addiction, depression, anxiety, and psychoses [54-
58].
Effect of different pharmacological 
manipulations of the endocannabinoid system in 
animal models of depression
Studies aimed at investigating the role of the endocannab-
inoid system in the physiopathology of depression have
demonstrated how both pharmacological activation of
the endocannabinoid transmission [59] and blockade of
CB1 receptors [60,61] produce an antidepressant-like
effect in animal models of depression, that are predictive
of antidepressant activity in humans.
Possible explanation for this discrepancy will be dis-
cussed.
Hill and Gorzalka [62] have demonstrated that direct or
indirect stimulation of CB1 receptor activity exerts antide-
pressant-like activity in the rat forced swimming test.
Indeed, they observed that the administration of the
uptake inhibitor AM404, the CB1receptor agonist HU210
and oleamide (which seems to be a competitive inhibitor
of FAAH [62]), display an antidepressant-like effect in the
rat forced swimming test similar to that observed follow-
ing the administration of the classical antidepressant des-
imipramine (DMI). These behavioural effects are
antagonized by the administration of AM251, a CB1
receptor blocker, suggesting that the stimulation of the
latter receptor leads to onset of the antidepressant-like
effect.
According to this hypothesis, it has been reported that
URB597, a potent FAAH inhibitor [63], elicits an antide-
pressant-like response in the mouse tail suspension test
and in the rat forced swimming test. These effects are
antagonized by the administration of SR141716A, a CB1
receptor blocker, further suggesting that the activation of
these receptors results in an antidepressant-like effect.
Moreover, the antidepressant-like effect produced by
URB597 was also observed after 4 days of sub-chronic
treatment with the drug.
The administration of URB597 in the rat forced swim-
ming test induced a behavioural pattern similar to that
observed with fluoxetine (decreased floating, increased
swimming but no affect on struggling) but at variance
with that displayed following DMI (increased struggling
but not swimming).
The behavioural effects elicited by URB597 appear to be
manifested following the stimulation of CB1 receptors
(attenuated by the CB1 receptor blocker SR141716A) by
anandamide.
Indeed, URB597 increases anandamide levels in the hip-
pocampus, prefrontal cortex (PFC) and midbrain, but
does not affect 2-AG levels. Moreover URB597 increases
the firing rate of 5HT neurons in the Dorsal raphe nucleus
(DRN), an effect becoming increasingly evident after
repeated administration and which is antagonized by
SR141716A. Repeated administration of URB597 also
increases 5HT release in the hippocampus. On the other
hand, URB597 produces a slow increase in the activity of
noradrenergic neurons in the locus coeruleus, but does
not affect noradrenaline release. These observations have
led the authors to suggest that the antidepressant-like
activity of URB597 may be mediated by the increase of
5HT and NA transmission.
However, this interpretation contrasts with the behav-
ioural observation made in the forced swimming test, in
which URB597 behaves in a similar fashion to fluoxetine,
a SSRI.
The chronic administration of URB597 exerts an antide-
pressant-like effect also in the chronic mild stress model
of depression with a concomitant increase of anandamide
levels in the midbrain, striatum, and thalamus [64].
However, recent reports refer to how URB597 failed to
elicit an antidepressant-like effect in the mice tail suspen-
sion test and in the forced swimming test. Likewise, no
antidepressant-like effect was manifested in FAAH-KO
mice [65]. However, this discrepancy may be explained by
the different experimental conditions used. In fact when
Lichtman's group performed experiments with altered
experimental conditions such as altered ambient light and
increased sample size they observed an antidepressant-
like effect in the mice tail suspension test of URB597 and
FAAH KO-mice[65].
Antidepressant-like properties have also been observed
following administration of ACEA (arachidonyl 2 chlo-
roethylamide) [66], a selective CB1 receptor agonist capa-
ble of eliciting an antidepressant-like effect in the mice
forced swimming test and in the head twitch response to
L5HTP.
Long term treatment with the CB1 agonist HU210 pro-
motes neurogenesis in the hippocampus of adult rats andClinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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elicits antidepressant-like behaviour in the forced swim-
ming test [67]. These effects are blocked by the CB1 recep-
tor antagonist AM281 and by hippocampal irradiation
which blocks neurogenesis.
These observations suggest that the antidepressant-like
effect displayed by the CB1 receptor agonist is related to
the promotion of hippocampal neurogenesis.
Interestingly, a similar effect has been reported after long
term administration of different classes of antidepressants
[15,16].
Taken together, the above observations suggest that the
activation of CB1 receptors through direct administration
of agonists or subsequent to increased endocannabinoid
levels at CB1 receptors may produce a potential antide-
pressant effect.
However, this hypothesis is in contrast with the findings
that also the blockade of CB1 receptors produces an anti-
depressant-like effect in animal models of depression.
The administration of AM251 has been reported to
decrease immobility in the mice tail suspension test in a
dose-dependent manner [68], an effect similar to that
observed after DMI.
On the contrary, the administration of the CB1 receptor
agonist CP55940 increases immobility in the mice tail
suspension test and counteracts the effect of AM251[68].
The latter compound also elicits an antidepressant like
effect in the rat forced swimming test [68] whilst produc-
ing no effect in CB1 receptor KO mice.
This previous observation led the authors to hypothesize
that the antidepressant-like behavioural effect elicited by
the CB1 receptors antagonists is strictly associated to the
presence of the CB1 receptors.
In accordance with the findings of Shearman et al [68], an
additional study reported how SR141716A increases
monoamine release in the prefrontal cortex and reduces
immobility in the mice forced swimming test when
administered at the relatively high dose of 3 mg/Kg but
not at the low doses of 0,3 mg/Kg and 1 mg/Kg [69].
A similar effect has been observed by Griebel et al [70].
Indeed, the administration of SR141716A at the dose of 3
and 10 mg/Kg does elicit an antidepressant-like effect in
the rat forced swimming test similar to that observed after
the administration of 30 mg/Kg of fluoxetine.
Finally, recent reports have disclosed that AVE1625, a
novel cannabiniod CB1 receptor antagonist [71], pro-
duces an antidepressant-like response in the mice forced
swimming test [71].
In an attempt to provide an explanation for these conflict-
ing results, further investigations aimed at evaluating the
effect of the increase of CB 1 activation and CB1 receptor
blockade under identical experimental conditions and
assessing the activation and blockade of CB1 receptors in
different animal models of depression should be per-
formed.
It has been suggested that the antidepressant-like effect
elicited by SR141716A may be produced following activ-
ity at the level of an as yet uncharacterised central cannab-
inoid receptor[59].
Accordingly it has been reported that SR141716A stimu-
lates neurogenesis also in CB1 KO mice [72], indicating
the involvement of a non CB1receptor. In fact,
SR141716A administered to Vanilloid receptor (VRI)-KO
mice failed to induce neurogenesis [72], suggesting that
rather than the neurogenic effect of SR141716A being
mediated by a non CB1 receptor, it is more likely regu-
lated by the stimulation of VRI receptors.
In addition, the possibility cannot be ruled out that the
efficacy of SR141716A in the forced swimming test could
be due to its ability to stimulate locomotor activity [73].
On the contrary, CB1 receptor agonists have been
reported to reduce locomotor activity, suggesting that
their effect in the forced swimming test cannot be consid-
ered a false positive secondary to the increased motor
activity [74].
On the other hand, CB1 KO mice have been reported to
display depressive-like behaviour [55].
Endocannabinoid system in animal models of 
depression
The majority of studies aimed at investigating the role of
endocannabinoid system in animal models of depression
report data suggesting that these models are associated
with a decrease in activity of the endocannabinoid system.
CB1 KO mice have been shown to be more susceptible to
developing depressive-like behaviour according to the
chronic mild stress model of depression [55]. This animal
model of depression measures the preference for a sucrose
solution following chronic exposure to mild stress. A
reduction in this preference is considered a symptom of
animal anhedonia. Thus, the decrease in sucrose intake by
CB1 KO mice suggests that the animals may posses aClinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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higher sensitivity towards developing anhedonia, a core
symtom of depression.
Accordingly, blockade of the endocannabinoid system
activity reduces the reinforcing properties of natural and
artificial stimuli [55,75], an effect that should result in
anhedonia.
The CB1 receptor KO mice are more susceptible to the
neurotoxic effect of kainic acid and display a marked
decrease in adult neurogenesis [72].
Furthermore, exposure to chronic stress is capable of
down-regulating the endocannabinoid system by reduc-
ing CB1 receptor density and 2-AG levels in the hippoc-
ampus [76].
However it has been reported that blockade of CB1 recep-
tors with SR141716A reduces the depressive-like behav-
iour observed after chronic exposure to mild stress [70].
Contrary to observations made as to the effect of different
pharmacological treatments in animal models of depres-
sion, only one report [70] has demonstrated a decrease in
depressive behaviour produced by the administration of
SR141716A following chronic exposure to mild stress.
Nevertheless the dose of SR141716A used in this experi-
ment was relatively high (10 mg/Kg per os).
Furthermore, CB2 receptors appear to be involved in the
physiopathology of depression. Indeed, it has been
reported that the expression of CB2 receptors is increased
in the mouse brain after 5 weeks of chronic mild stress
[42].
Effects of antidepressant drugs on the 
endocannabinoid system
To date very few studies have been published with regard
to the effect produced by the currently available antide-
pressant drugs on the endocannabinoid system.
Repeated administration of fluoxetine causes a decrease of
cannabinoid CB1 gene expression in the caudate-puta-
men [77]. The authors suggest that fluoxetine may inhibit
anandamide uptake [77], thus increasing the availability
of the endocannabinoid at the level of the CB1 receptor;
increased activation of the receptor would likely result in
down-regulation of cannabinoid CB1 receptors gene
expression [77].
On the contrary, it has been reported that chronic fluoxe-
tine causes an up-regulation of CB1 receptors in the Pre-
frontal cortex (PFC), [78,79], chronic DMI up-regulates
CB1 receptors in the hypothalamus and hippocampus
[78,79], tranylcypromine (a MAOI) decreases the levels of
anandamide in the PFC, hippocampus and hypothala-
mus, and increases CB1 receptor binding in PFC and the
hippocampus, but not in the hypothalamus [78,79].
The results suggest that tranylcypromine induces hypo-
activity of the endocannabinoid system in the hypothala-
mus, but, similar to fluoxetine and DMI, produces an up-
regulation of CB1 receptors in other brain areas.
Moreover, the observation that chronic fluoxetine acti-
vates G protein signal transduction coupled to CB1 recep-
tors at different levels [80] adds further support to the
hypothesis that fluoxetine activates the endocannabinoid
system.
A recent study published by Hill et al [81] demonstrated
that chronic administration of DMI does not modify
endocannabinoid levels in the PFC, hippocampus,
hypothalamus, or amygdala, but increases CB1 receptor
density in the hippocampus and hypothalamus.
Moreover, rats subjected to a 5 minutes swimming test
displayed an increase in corticosterone levels and the
induction of c-fos in the Paraventricular nucleus(PVN) of
the hypothalamus.
Chronic DMI counteracts these stress-induced effects on
the HPA-axis. The effect of DMI is mediated by the activa-
tion of CB1 receptors being blocked by the administration
of the CB1 receptor antagonist AM251.
This finding suggests that antidepressant drugs may
restore the HPA-axis by stimulating CB1 receptors, thus
stimulating the endocannabinoid system.
However, Gobshtis et al [82] have demonstrated that the
antidepressant -like effect produced by DMI and fluoxet-
ine in the mice forced swimming test was not antagonized
by SR141716A.
This finding is in line with the observation of Sherman et
al [68] who demonstrated that the antidepressant-like
effect of DMI was also displayed in CB1 KO mice.
The above observation suggests the impossibility of gener-
alising the involvement of CB1 receptor in the action of
DMI, tending rather to be limited to producing an effect
on the regulation of the HPA-axis.
Recently, a very complex action of electroconvulsive shock
(ECS), the most powerful antidepressant treatment, on
the endocannabinoid system has been reported [83]. A
single administration of ECS produces a reduction in the
affinity of CB1 receptors in the PFC, hippocampus,
hypothalamus and amigdala, reduces anandamide levelsClinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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in the PFC and hippocampus, and FAAH activity in the
PFC. On the contrary, it increases the density of CB1
receptors in the amigdala. After chronic administration of
10 days ECS further reduces the anandamide levels in the
PFC as well as the density of CB1 receptors, but enhances
the sensitivity of CB1 receptors in the amigdala.
Clinical studies
To date, the only clinical trials present in the literature per-
formed using synthetic compounds capable of influenc-
ing the endocannabinoid system are those aimed at
evaluating the efficacy of rimonabant in obesity [84,85].
The rationale underlying these studies was based on the
observation that the blockade of CB1 receptors is associ-
ated to a reduction of reinforcing properties elicited by
both natural and artificial stimuli [55,75].
A clinical study carried out by Despress et al [84] includes
depression among the side effects resulting in discontinu-
ation of treatment. This observation leads us to hypothe-
size that blockade of CB1 receptors may be capable of
inducing depression in humans. This is more than a mere
speculation if we consider that the Food and Drug Admin-
istration (FDA)'s Endocrinologic and Metabolic Drugs
Advisory Committee meeting on June 13, 2007, rewieving
numerous studies and post-marketing report did not rec-
ommended approval of Rimonabant mainly because of
their concerns about the ability of the drug to increase the
risk of depression and "suicidality"[86] This effect appears
to be present not only in people with a history of depres-
sion but also in patients without history of depression,
since some clinical trials with rimonabant do not include
patients with history of depressive disorders, with a
depressive episode or those in therapy with antidepres-
sant drugs.
Moreover, the European Medicines Agency(EMEA)'s
Committee for Medicinal Products for Human
use(CHMP) on July 19, 2007 decided to include " ongo-
ing major depression illness and/or ongoing antidepres-
sant treatment " among the contraindications to the use of
rimonabant; moreover, the administration of the drug
must be stopped if depression develops[87].
To the best of our knowledge, however, no clinical studies
have been performed to study mood disorders using syn-
thetic drugs capable of interacting with the endogenous
cannabinoid system. Although several anecdotal reports
have been published with regard to the effects produced
by cannabinoids on depression and or mania, to date, no
clinical trials have been performed to investigate the ther-
apeutic use of cannabinoids in depression and or mania
[88].
The previously mentioned anecdotal reports describe
both antimanic [89] and antidepressive effects[90] of can-
nabis. Conversely, other reports have disclosed how can-
nabis may induce mania [91,92] and psychosis [93],
while substance abuse increases the severity of mood dis-
orders [94]and even the risk of suicide[95].
Interestingly, Hungund et al [96] found an up-regulation
of CB1 receptors associated to a concomitant increase in
the CB1 receptor mediated GTP binding in the PFC of
depressed suicides, suggesting an important role for
enhanced endocannabinoid activity in the pathogenesis
of suicide. Accordingly, Vinod et al [97] reported elevated
levels of endocannabinois, CB1 receptors and CB1 recep-
tors mediated GTP binding in the PFC of alcoholic sui-
cides, adding further support to an involvement of
hyperactivity of the endocannabinoid system in suicides
[98].
Very recently, Hill et al [99] found that serum 2-AG is
reduced in patients suffering from major depression, a
reduction strictly correlated with the duration of the
depressive episode. On the contrary, serum anandamide
levels in these patients remain unchanged, whereas
patients with high anxiety scores are characterised by
lower levels of anandamide.
Significantly elevated serum anandamide levels were
revealed in patients with minor depression. However, it
must be pointed out that the same authors found (" in a
second experiment ") a decrease of both anandamide and
2-AG in women affected by major depression.
Exposure of these patients to psychological stress pro-
duced an initial increase in 2AG and anandamide levels
followed by a subsequent decrease.
Finally, Miller et al [100] found that 2-AG serum levels
were decreased in women with major depression, this
decrease being correlated with the duration of the depres-
sive episode. On the contrary women suffering from
minor depression displayed significantly high serum lev-
els of anandamide.
On the basis of these observations, the authors suggest
that modifications to the central endocannabinoid system
vary in the presence of minor or major depression, the sys-
tem becoming hypoactive in major depression and dis-
playing an increased activity in minor depression.
Accordingly, Koethe et al[101] found a decrease of CB1
receptor density in the glial cells of the grey matter in the
brain of post-mortem patients suffering from major
depression.Clinical Practice and Epidemiology in Mental Health 2007, 3:25 http://www.cpementalhealth.com/content/3/1/25
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Conclusion
The preclinical and clinical data presented in the present
review may suggest involvement of the endocannabinoid
system in the pathogenesis of depression.
Preclinical data were derived exclusively from studies per-
formed in animal models of depression, the majority of
which used the rat forced swimming test model of depres-
sion, reporting largely conflicting results.
Indeed, both the activation and the blockade of the endo-
cannabinoid system have been reported to produce anti-
depressant-like behaviour. Thus, on the mere basis of the
findings reported, it is difficult to hypothesise more spe-
cifically as to the role played by endocannabiniods in the
pathogenesis of depression.
Additional studies should be performed in different ani-
mal models of depression to elucidate whether an
increased or decreased activity of the endocannabinoid
system might exert a potential antidepressant effect and
whether, in turn, depression may be associated with an
enhanced or a deficient functioning of this system.
However, studies performed on the endocannabinoid sys-
tem in animal models of depression, suggest an associa-
tion between a reduced activity of the endocannabinoid
system and depressive behaviour induced by chronic mild
stress model.
However, to better support this hypothesis, also in this
case, similar studies should be performed using different
animal models of depression.
Studies published to date on the effect of classical antide-
pressants on the endocannabinoid system seem to suggest
an increased transmission induced by antidepressants at
CB1 receptor level although negative findings have also
been reported.
Of particular interest is the finding that the stimulation of
cannabinoid CB1 receptors promotes neurogenesis while
CB1 KO mice show impaired adult neurogenesis.
These findings are in line with the more recently proposed
theories on the neurobiology o f depression.
Clinical data available to date suggest that the endocan-
nabinoid system might be implicated in the pathogenesis
of suicide, apparently associated with a hyperactivity of
the endocannabinoid system. Indeed, this observation
also suggests that enhanced endocannabinoid activity
might be associated with impulsive behaviour, a charac-
teristic of suicide, rather than with depression.
Moreover, lower levels of 2-AG have been found in major
depression while minor depression appears to be associ-
ated with high levels of serum anandamide.
With regard to the effect of pharmacological manipula-
tion of the endocannabinoid system in the treatment of
depression, the literature reports mainly anecdotal obser-
vations proposing both antidepressive and antimanic
effects for marijuana. Habitual marijuana users tend to
manifest mania, worsening of mood disorder course or
psychosis, suggesting that cannabinoids may produce a
stimulant effect manifested not only in the presence of
euphoria but also in the presence of mania and psychosis.
In line with this hypothesis is the report that blockade of
cannabinoid CB1 receptors might induce depression.
Indeed, it is tempting to speculate that depression might
be associated with a decrease of the endocannabinoid sys-
tem while mania is manifested subsequent to a hyperac-
tive functioning of the system. According to this
hypothesis it has been recently reported that SR141716A
antagonizes amphetamine-induced arousal in the Cebus
monkey [102]. To further investigate this hypothesis,
detailed studies are currently in progress in our laboratory
with the aim of evaluating the effect of CB1 receptor
blockers in animal models of mania.
To conclude, although some preclinical and clinical evi-
dence may seem to suggest an involvement of the endo-
cannabinoid system in the physiopathology of
depression, it is undeniable that additional studies aimed
at better elucidating the role of the endocannabinoid sys-
tem in the neurobiology of depression are mandatory.
The latter studies should focus particularly on clarifying
the role of the different pharmacological manipulation of
the endocannabinoid system in different animal models
of depression and mania. Furthermore, studies performed
to investigate the effect of different classes of currently
used antidepressants and mood stabilizers on the various
stages of endocannabinoid transmission should prove to
be of great interest.
Lastly, the relevance of serum levels of endocannabinoids
throughout the different phases of manic depressive dis-
orders should be ascertained in order to better clarify the
role of these neuromodulatory compounds in the neuro-
biology of depression. Moreover, we are confident that
neuroimagine studies should provide very interesting
results to elucidate the role of the endocannabinoid sys-
tem in the different phases of mood disorders.
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